Torrent Pharmaceuticals Ltd Share Price

Pharmaceuticals

NSE: TORNTPHARM Large Cap ISIN: INE685A01028

As on 18 November 2025 at 23:55 IST

₹3,792.50

-26.90

(-0.70%)

Sell Buy

Torrent Pharmaceuticals Q1 FY26 Results:

Net profit for the period increased 20% to ₹548 crores in Q1 FY26, from ₹457 crores in Q1 FY25. Total income for the quarter increased 9% year-on-year to ₹3141 crores from ₹2883 crores.

About Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd. is a prominent Indian pharmaceutical company. It engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations. Founded in the year 1959, the company has decades of experience in the industry. The headquarters of the company is located in Ahmedabad, Gujarat, India. Torrent Pharmaceuticals' main products include branded and unbranded generic pharmaceuticals. They have a significant presence in various therapeutic areas such as gastrointestinal, cardiovascular, central nervous system, women's healthcare, gynaecology, diabetology, oncology, pain management, and anti-infective segments. Torrent Pharmaceuticals Ltd. falls under the pharmaceuticals sector. +

Over 1 Month

6.56%

Over 6 Months

15.64%

Over 1 Year

22.98%

Over 3 Years

134.61%

Torrent Pharmaceuticals Ltd Summary

Close ₹3,819.40

Open ₹3,859

High ₹3,859

Low ₹3,807.10

Volume 1,53,147

Net Turnover (in Cr) ₹58.54

52Wk High ₹3,882.20

52Wk Low ₹2,886.45

52Wk High / Low

2,886.45

3,882.20

Torrent Pharmaceuticals Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹1,29,260.05

EPS (TTM) 63.06

Book Value (BV) 249.84

Div. Yield 0.16 %

P/E (TTM) 61.30

Price/Book Value 15.28

Delivery % 67.99 %

Face Value 5

Key Ratios

PE Ratio 57.99

PB Ratio 14.42

EV to Sales 11.57

PEG Ratio 1.48

ROA 17.86

ROE 26.18

Debt-Equity 0.41

Net Profit Margin 19.50

Operating Profit Margin 37.01

Torrent Pharmaceuticals Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	11,539.36	10,785.75	9,665.29	8,704.60	8,061.48
Total Expenses	8,842.34	8,522.02	7,818.13	6,993.99	6,535.22
Profit Before Tax	2,672.81	2,352.11	1,847.16	1,225.91	1,526.26
Profit After Tax	1,911.25	1,656.38	1,245.23	777.18	1,251.88
Operating Profit After Depreciation	2,949.33	2,617.29	2,180.60	1,965.67	1,879.20

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	8,057.78	8,217.82	8,198.61	6,508.13	7,210.11
Total Non Current Assets	9,367.17	9,449.10	9,698.13	7,934.85	8,553.15
Total Current Assets	5,622.57	5,611.48	5,313.72	5,164.99	5,521.50
Total Assets	14,989.74	15,060.58	15,011.85	13,099.84	14,074.65
Total Shareholder's Fund	7,590.69	6,856.15	6,198.07	5,952.95	5,837.17

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	2,585.11	3,266.08	2,368.13	1,802.99	2,005.35
Net Cash Used In Investing Activities	-548.78	-159.83	-2,335.36	-196.10	-443.82
Net Cash Used In Financing Activities	-2,297.99	-2,779.64	77.36	-1,781.05	-1,650.79

Profit and Loss

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	9,713.94	8,624.26	7,777.08	6,946.49	6,568.91
Total Expenses	7,079.55	6,707.69	6,200.06	5,480.28	5,202.80
Profit Before Tax	2,610.18	1,916.57	1,577.02	1,466.21	1,366.11
Profit After Tax	1,888.06	1,357.08	1,051.39	991.45	1,137.85
Operating Profit After Depreciation	2,847.79	2,219.61	1,874.70	1,702.50	1,700.23

Balance Sheet

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Fixed Assets	7,590.29	8,008.21	7,994.88	6,275.21	6,774.51
Total Non Current Assets	8,492.96	8,635.53	8,944.85	7,092.51	7,619.16
Total Current Assets	4,348.80	3,741.06	3,927.08	4,060.05	4,141.88
Total Assets	12,841.76	12,376.59	12,871.93	11,152.56	11,761.04
Total Shareholder's Fund	7,592.50	6,828.76	6,455.96	6,345.42	6,030.10

Cash Flow

Particulars (in ₹ Cr.)	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash From Operating Activities	2,574.50	2,893.10	2,265.41	2,140.10	1,572.89
Net Cash Used In Investing Activities	-470.09	-296.07	-2,325.75	-159.70	-316.28
Net Cash Used In Financing Activities	-2,104.46	-2,577.57	80.74	-1,977.27	-1,581.20

Particulars (in ₹ Cr.)	2025-09	2025-06	2025-03	2024-12	2024-09
Total Revenue	3,302	3,178	2,959	2,809	2,889
Total Expenses	2,219	2,146	1,995	1,895	1,950
Profit Before Tax	791	738	665	691	661
Profit After Tax	591	548	498	503	453
Operating Profit after Depreciation	1,056	995	946	947	923

Particulars (in ₹ Cr.)	2025-09	2025-06	2025-03	2024-12	2024-09
Total Revenue	2,762	2,616	2,433	2,377	2,434
Total Expenses	1,690	1,637	1,565	1,490	1,513
Profit Before Tax	806	742	622	651	670
Profit After Tax	597	551	474	485	460
Operating Profit after Depreciation	1,045	974	883	890	914

Torrent Pharmaceuticals Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 3,798

S2 3,776.60

S3 3,746.10

Pivot 3,828.50

R1 3,849.90

R2 3,880.40

R3 3,901.80

Moving Average

20 SMA 3,657.88

50 SMA 3,605.08

100 SMA 3,562.28

200 SMA 3,372.96

Torrent Pharmaceuticals Ltd Corporate Actions

Torrent Pharmaceuticals Ltd

₹6.0/Share

Announcement Date 20 Jun 2025

Record Date 20 Jun 2025

Div Yield 120%

AGM Date: 27 Jul 2021

AGM 27/07/2021 Please find enclosed herewith the copies of Newspaper cuttings published in Financial Express (English) on 4th July, 2021 and Financial Express (Gujarati) on 5th July, 2021 in connection with the 48th Annual General Meeting and E-Voting Procedure. (As Per BSE Announcement dated on 05.07.2021) Proceedings of 48th Annual General Meeting of the Company held on 27th July, 2021 (As Per BSE Announcement dated on 27.07.2021) Declaration of Voting results of 48th AGM (AS Per BSE Announcement Dated on 28.07.2021) Torrent Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here (As Per BSE Announcement Dated 29.07.2021)

AGM Date: 29 Jul 2022

AGM 29/07/2022 Please find attached herewith soft copy of the Integrated Annual Report 2021-22 (comprising of Notice calling 49th Annual General Meeting (AGM) along with Audited Financial Statements, Directors'' Report, Auditors' Report, etc.) of Torrent Pharmaceuticals Limited ('the Company') in compliance with Regulation 34(1)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Listing Regulations'). (As Per BSE Announcement Dated on 04.07.2022) Please find enclosed herewith the copies of Newspaper cuttings published in Financial Express (English & Gujarati) on 5th July, 2022 in connection with the 49th Annual General Meeting and E-Voting Procedure. (As Per BSE Announcement Dated on 05/07/2022) Declaration of Results of Voting Proceedings of 49th Annual General Meeting of the Company held on 29th July, 2022 (As per BSE Announcement Dated on 29/07/2022) Torrent Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. (As Per BSE Announcement Dated on 30/07/2022)

AGM Date: 07 Aug 2023

Newspaper advertisement - Intimation of the 50th Annual General Meeting of the Company through Video-Conferencing / Other Audio Visual Means ('VC / OAVM') facility. Please find attached herewith soft copy of the Integrated Annual Report 2022-23 (comprising of Notice calling 50th Annual General Meeting (AGM) along with Audited Financial Statements, Directors'' Report, Auditors' Report, etc.) of Torrent Pharmaceuticals Limited ('the Company') in compliance with Regulation 34(1)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Listing Regulations'). The above is for your information and record. (As Per BSE Announcement dated on 14.07.2023) Please find enclosed herewith the copies of Newspaper cuttings published in Financial Express (English & Gujarati) on 15th July, 2023 in connection with the 50th Annual General Meeting and E-Voting Procedure. (As Per BSE Announcement Dated on 15.07.2023) Appointment of Nikhil Khattau as an Independent Director of the Company Proceeding of 50th Annual General meeting of the Company held on 07.08.2023 (As per BSE Announcement Dated on 07/08/2023) Declaration of voting result (As per BSE Announcement Dated on 08/08/2023) Declaration of voting result and Scrutinizer Report (As per BSE Announcement Dated on 09/08/2023) Conclusion time of the 50th Annual General Meeting of the Company (As Per BSE Announcement Dated on 09/04/2024)

AGM Date: 23 Jul 2024

Newspaper Advertisement - Intimation of the 51st Annual General Meeting of the Company through Video Conferencing / Other Audio Visual Means ('VC / OAVM') facility Submission of Annual Report for FY 2023-24 and intimation of voting through electronic means (As Per BSE Announcement Dated on: 29/06/2024) Declaration of Voting Results (As Per BSE Announcement dated on 24.07.2024)

AGM Date: 28 Jul 2025

Submission of Annual Report for FY 2024-25 and intimation of voting through electronic means Proceedings of 52nd AGM held on 28-jul-25 Appointment of Secretarial Auditors (As per BSE Announcement Dated on 28/07/2025) Declaration of Voting result and scrutinizer report (As Per BSE Announcement Dated on: 29/07/2025)

Torrent Pharmaceuticals Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceutical Industries Ltd	₹1,763.70	₹4,23,170.71
Divis Laboratories Ltd	₹6,523.25	₹1,73,171.79
Cipla Ltd	₹1,536.25	₹1,24,093.85
Dr Reddys Laboratories Ltd	₹1,244.50	₹1,03,868.61
Zydus Lifesciences Ltd	₹934.30	₹94,012.44

Torrent Pharmaceuticals Ltd Top Mutal Funds Invested

Fund Name	AUM
Franklin India Large Cap Fund	3.80%
SBI Healthcare Opportunities Fund	3.49%
HDFC Large Cap Fund	2.85%
ICICI Pru Nifty Next 50 Index Fund	1.59%
UTI-Flexi Cap Fund	1.03%

Torrent Pharmaceuticals Ltd News

Torrent Pharma jumps after Q2 profit rises 30% YoY

Torrent Pharmaceuticals jumped 7.14% to Rs 3834.90 after the company reported a robust set of results for Q2 FY26, driven by strong branded business performance across key markets.

10 Nov 2025, 02:27 pm

Torrent Pharma Q2 profit rises 30% YoY

Torrent Pharmaceuticals reported a robust set of results for Q2 FY26, driven by strong branded business performance across key markets.

08 Nov 2025, 04:48 pm

Torrent Pharmaceuticals to discuss results

On 7 November 2025

28 Oct 2025, 10:46 am

Torrent Pharmaceuticals Ltd spurts 0.06%, gains for five straight sessions

Torrent Pharmaceuticals Ltd is quoting at Rs 3586.6, up 0.06% on the day as on 12:44 IST on the NSE. The stock is up 5.72% in last one year as compared to a 4.39% gain in NIFTY and a 3.13% gain in the Nifty Pharma.

20 Oct 2025, 01:00 pm

Torrent Pharmaceuticals allots commercial paper of Rs 200 cr

24 Sep 2025, 07:12 pm

Torrent Pharmaceuticals Ltd Stock Analysis

Annual revenue for Torrent Pharmaceuticals Ltd increased by 12.64% to ₹9,713.94 crore in FY 2025 from ₹8,624.26 crore in FY 2024.
Annual Net Profit for Torrent Pharmaceuticals Ltd increased by 39.13% to ₹1,888.06 crore in FY 2025 from ₹1,357.08 crore in FY 2024.
Promoter Shareholding in Torrent Pharmaceuticals Ltd remains unchanged by 0.00% in the most recent quarter, from 68.31% in June 2025 to 68.31% in September 2025.
Torrent Pharmaceuticals Ltd delivered a 1-year return of 22.98% compared to the Nifty 50, which provided a return of 10.91% as of the last trading session.
Torrent Pharmaceuticals Ltd share price moved down by 0.70% from its previous close of INR ₹3,819.40. The latest Torrent Pharmaceuticals Ltd share price is INR ₹3,792.50.
Torrent Pharmaceuticals Ltd share price today has been at a low of 3,787.50 and a high of 3,847.90. Over the past 52 weeks, the Torrent Pharmaceuticals Ltd share price has seen a low of 2,886.45 and a high of 3,882.20.

About Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd. is a prominent Indian pharmaceutical company. It engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations. The company operates in the pharmaceutical sector. Additionally, it has a significant presence in various therapeutic areas. This includes gastrointestinal, cardiovascular, gynaecology, diabetology, pain management, and anti-infective segments.
Torrent Pharmaceuticals Ltd. falls under the pharmaceuticals sector. The company was founded in 1959 by U. N. Mehta as Trinity Laboratories. It was later renamed Torrent Pharmaceuticals in 1971. With years of experience, Torrent Pharma has established itself as a key player in the industry.
The headquarters of Torrent Pharmaceuticals Ltd. is located in Ahmedabad, Gujarat, India. The company is promoted by the Torrent Group, with key promoters including Sudhir Mehta and Samir Mehta. They serve as chairman emeritus and chairman of the company. The other managerial promoters of the company include:

Aman Samir Mehta
Jinesh Shah
Jinal Mehta

Torrent Pharmaceuticals' main products include branded and unbranded generic pharmaceuticals. Its products are used in various therapeutic areas. The company also provides contract manufacturing services.
Torrent Pharmaceuticals Ltd. is a significant player in the pharmaceuticals sector, with a significant market capitalization. The company is recognized for its innovative solutions and commitment to quality, making it a major player in the industry. Its robust capabilities and extensive product portfolio have further positioned it as a key player in the industry. However, Torrent Pharmaceuticals may not be the largest by market capitalization.
The promoter shareholding in Torrent Pharmaceuticals Ltd. stands at 71.25%, which is entirely held by Torrent Investments Private Limited. This indicates strong promoter commitment to the business.
The registered office of Torrent Pharmaceuticals Ltd. is located at Torrent House, Off Ashram Road, Ahmedabad - 380009, Gujarat, India. Its registrar & transfer agent is TSR Darashaw Consultants Pvt. Ltd.
Torrent Pharmaceuticals Ltd. is a well-established pharmaceutical company in India. The company is known for its comprehensive range of products and strong market presence. Its commitment to innovation and quality has strengthened its position as a trusted name in the industry.

Future Strategy of the Company

Torrent Pharmaceuticals Ltd. stands at a critical juncture in its evolutionary journey. This is because it is poised to leverage its decades of legacy in pharmaceutical excellence into a transformative future strategy. With a significant market capitalization and a strong promoter shareholding, the company is strategically positioning itself to navigate the complex and dynamic global pharmaceutical landscape. This is accomplished through its innovative approaches, technological integration, and comprehensive market expansion.
Strategic Market Expansion and Diversification The company's future strategy centres on strategic market diversification across many therapeutic segments. Torrent Pharmaceuticals aims to strengthen its existing strongholds in various therapeutic areas. This includes cardiovascular, women's healthcare, oncology and diabetology. The organization's approach involves developing a balanced portfolio that combines branded and generic pharmaceutical formulations. This ensures resilience and adaptability in rapidly changing market conditions.
A key strategic focus will be geographical expansion, particularly in international markets. By leveraging its strong research and development capabilities, Torrent plans to enhance its global footprint. They are targeting regulated markets like the US, Europe and emerging pharmaceutical markets in Asia and Africa. The company intends to achieve this through a multi-pronged approach. This approach involves strategic partnerships and targeted acquisitions. Also, they localized product development strategies tailored to specific regional healthcare needs.
Technological and Innovation Leadership Torrent Pharmaceuticals Ltd. is committed to positioning itself as a technological leader in pharmaceutical innovation. The company's future strategy emphasizes significant investments in research and development. This is because they focus on developing advanced generic formulations and innovative solutions. Torrent aims to create a robust innovation ecosystem that can generate high value through differentiated pharmaceutical products. This is done by establishing state-of-the-art research facilities and fostering collaborations with academic and research institutions.
The organization plans to leverage emerging technologies to optimize its generic pharmaceutical production. The advanced technological integration will enable more efficient, precise, and cost-effective pharmaceutical development. As a result, it will potentially reduce the time-to-market and enhance the overall product quality.
Sustainability and Operational Excellence Future strategic considerations for Torrent Pharmaceuticals Ltd. include a strong emphasis on sustainability and operational excellence. The company aims to develop environmentally responsible manufacturing processes. Additionally, their goal is to implement advanced quality control mechanisms. Thus, Torrent is investing in green manufacturing technologies and adopting circular economy principles.
Digital Transformation and Healthcare Integration Recognizing the transformative potential of digital technologies, Torrent Pharmaceuticals Ltd. plans to integrate advanced digital solutions across its operations. This includes developing digital health platforms and exploring telemedicine opportunities. They also aim to create patient-centric digital interfaces that help improve healthcare facilities.
Torrent Pharmaceuticals Ltd.'s future strategy represents a sophisticated approach to pharmaceutical development. The company is positioning itself as a pharmaceutical manufacturer and a comprehensive healthcare solutions provider. This is because it is balancing technological innovation, strategic marketing, and digital transformation. The company's forward-looking approach has poised it to redefine the boundaries of pharmaceutical excellence in the coming decades.